During pre-market trading on Tuesday, Jaguar Health Inc. (JAGX) climbed 2.55% to $1.61. The Jaguar Health stock finished the last trading session down -4.85% at $1.57. The price range for JAGX stock was between $1.55 and $1.65. During the past 100 days, JAGX stock traded 3.33 million shares daily but the volume of 11.44 million shares traded in the last session was much higher than that. In the past five days, JAGX shares have gained 3.29%, but have lost -17.80% over a month. We can use recent developments to provide a deeper understanding of the company as JAGX stock rose despite no current news.

What is the latest from JAGX?

As a commercial stage pharmaceuticals company, Jaguar Health aims to develop plant-based, non-opiod, and sustainably-derived prescription medications that are safe and effective for people and animals with GI distress, especially chronic, debilitating diarrhea. JAGX’s wholly-owned subsidiary, Napo Pharmaceuticals, Inc., is focused on the development and commercialization of plants harvested from rainforest areas for use in gastrointestinal pharmaceuticals.

As the only oral plant-based prescription medicine approved under FDA Botanical Guidance, the Mytesi product developed by JAGX provides symptomatic relief of noninfectious diarrhea associated with HIV/AIDS in adults on antiretroviral therapy. The Napo EU S.p.A. subsidiary of Napo Pharmaceuticals aims to expand access to crofelemer in Europe.

For the third time, Jaguar Health’s annual shareholders’ meeting on May 13 has been adjourned due to a lack of quorum.

• Hence, the adjourned meeting of JAGX will now be held on August 6, 2021.
• JAGX will hold its annual meeting at its San Francisco office.
• The record date used to determine which JAGX stockholders will be eligible for the Annual Meeting was April 12, 2021.
• The proposals have been generally well received by JAGX stockholders.
• A JAGX stockholder who does not intend to revoke or change his or her previously delivered proxy is not required to take any action.
• During the annual meeting, JAGX encouraged its eligible stockholders who still have not voted their shares / provided voting instructions to their broker / other record holder to do so.
• The company counted on their participation as to reach quorum, JAGX still needs to receive votes from 2.9% of its eligible common stockholders.

How can JAGX shareholders vote?

There are several voting options available to Jaguar Health (JAGX) shareholders. Shareholders of JAGX can vote by internet at http://www.voteproxy.com or by phoning 800-776-9437 24 hours a day or submitting a proxy card properly executed. The street name holders of JAGX stock have the option of voting via their broker. In the process of preparing the proposals for stockholders to vote on at the Annual Meeting, JAGX has not made any changes.